Logo image of PLUR

PLURI INC (PLUR) Stock Fundamental Analysis

USA - NASDAQ:PLUR - US72942G2030 - Common Stock

3.8799 USD
+0.01 (+0.31%)
Last: 10/23/2025, 5:29:06 PM
Fundamental Rating

2

Overall PLUR gets a fundamental rating of 2 out of 10. We evaluated PLUR against 534 industry peers in the Biotechnology industry. PLUR may be in some trouble as it scores bad on both profitability and health. PLUR shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PLUR has reported negative net income.
PLUR had a negative operating cash flow in the past year.
In the past 5 years PLUR always reported negative net income.
In the past 5 years PLUR always reported negative operating cash flow.
PLUR Yearly Net Income VS EBIT VS OCF VS FCFPLUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -58.38%, PLUR is in line with its industry, outperforming 44.38% of the companies in the same industry.
Industry RankSector Rank
ROA -58.38%
ROE N/A
ROIC N/A
ROA(3y)-56.03%
ROA(5y)-56.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLUR Yearly ROA, ROE, ROICPLUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K

1.3 Margins

PLUR's Gross Margin of 48.95% is fine compared to the rest of the industry. PLUR outperforms 75.47% of its industry peers.
In the last couple of years the Gross Margin of PLUR has declined.
PLUR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-13.31%
PLUR Yearly Profit, Operating, Gross MarginsPLUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K -100K

More info and screens

0

2. Health

2.1 Basic Checks

PLUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLUR has more shares outstanding
PLUR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PLUR has a worse debt to assets ratio.
PLUR Yearly Shares OutstandingPLUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
PLUR Yearly Total Debt VS Total AssetsPLUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -17.79, we must say that PLUR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PLUR (-17.79) is worse than 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.79
ROIC/WACCN/A
WACC7.41%
PLUR Yearly LT Debt VS Equity VS FCFPLUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

PLUR has a Current Ratio of 0.68. This is a bad value and indicates that PLUR is not financially healthy enough and could expect problems in meeting its short term obligations.
PLUR has a worse Current ratio (0.68) than 91.01% of its industry peers.
PLUR has a Quick Ratio of 0.68. This is a bad value and indicates that PLUR is not financially healthy enough and could expect problems in meeting its short term obligations.
PLUR has a worse Quick ratio (0.68) than 90.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.68
PLUR Yearly Current Assets VS Current LiabilitesPLUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

PLUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.70%, which is quite impressive.
PLUR shows a strong growth in Revenue. In the last year, the Revenue has grown by 309.82%.
Measured over the past years, PLUR shows a very strong growth in Revenue. The Revenue has been growing by 63.03% on average per year.
EPS 1Y (TTM)26.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.23%
Revenue 1Y (TTM)309.82%
Revenue growth 3Y63.03%
Revenue growth 5YN/A
Sales Q2Q%314.58%

3.2 Future

Based on estimates for the next years, PLUR will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.63% on average per year.
Based on estimates for the next years, PLUR will show a very strong growth in Revenue. The Revenue will grow by 113.54% on average per year.
EPS Next Y87.65%
EPS Next 2Y37.16%
EPS Next 3Y19.26%
EPS Next 5Y12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y90.39%
Revenue Next 5Y113.54%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PLUR Yearly Revenue VS EstimatesPLUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
PLUR Yearly EPS VS EstimatesPLUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLUR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLUR Price Earnings VS Forward Price EarningsPLUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLUR Per share dataPLUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PLUR's earnings are expected to grow with 19.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.16%
EPS Next 3Y19.26%

More info and screens

0

5. Dividend

5.1 Amount

PLUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLURI INC

NASDAQ:PLUR (10/23/2025, 5:29:06 PM)

3.8799

+0.01 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-17 2025-09-17/amc
Earnings (Next)11-10 2025-11-10
Inst Owners19.6%
Inst Owner Change0%
Ins Owners40.66%
Ins Owner Change4.37%
Market Cap31.66M
Revenue(TTM)1.34M
Net Income(TTM)-22583000
Analysts82.86
Price Target12.24 (215.47%)
Short Float %0.53%
Short Ratio2.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-42.97%
Revenue NY rev (3m)-60.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.32
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.23
OCFYN/A
SpS0.16
BVpS-0.84
TBVpS-1.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.95%
FCFM N/A
ROA(3y)-56.03%
ROA(5y)-56.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-13.31%
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 512.03%
Cap/Sales 121.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.68
Altman-Z -17.79
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)237.36%
Cap/Depr(5y)153.18%
Cap/Sales(3y)103.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.23%
EPS Next Y87.65%
EPS Next 2Y37.16%
EPS Next 3Y19.26%
EPS Next 5Y12.63%
Revenue 1Y (TTM)309.82%
Revenue growth 3Y63.03%
Revenue growth 5YN/A
Sales Q2Q%314.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y90.39%
Revenue Next 5Y113.54%
EBIT growth 1Y-0.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.05%
OCF growth 3YN/A
OCF growth 5YN/A